Treatment with cyclosporine A improves SLE disease activity of Japanese patients with diffuse proliferative lupus nephritis

Clinical Nephrology

Volumn 76, Issue 2, 2011, Pages 136-143

  Kamijo, Y ^a   Hashimoto, K ^a   Takahashi, K ^a   Ehara, T ^a   Shigematsu, H ^a   Higuchi, M ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclosporine; Kidney function; Lupus nephritis; Proteinuria; SLE disease activity

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; PROTEIN;

ADULT; APHERESIS; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG PULSE THERAPY; DRUG TOLERABILITY; FEMALE; HERPES ZOSTER; HUMAN; HYPOCOMPLEMENTEMIA; INFLUENZA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PROTEINURIA; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KIDNEY; KIDNEY FUNCTION TESTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80052385954     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN106920     Document Type: Article

References (21)

1. Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant. 2009; 24: 15-20.
2. Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporin a Neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol. 1998; 37: 217-221.
3. Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S, Manno C, Altieri P, Ferrara R, Greco S, Ponticelli C. A randomized pilot trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol. 2006; 1: 925-932.
4. Austin HA III, IIIei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009; 20: 901-911.
5. Dostál C, Tesar V, Rychlík I, Zabka J, Vencovský J, Bartûnková J, Stejskalová A, Tegzova D. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus. 1998; 7: 29-36.
6. Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E, Merta M, Rysava R, Tesar V. Treatment of lupus nephritis with cyclosporine - an outcome analysis. Kidney Blood Press Res. 2007; 30: 124-128.
7. Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, Szeto CC, Lui SF. Long-term treatment of lupus nephritis with cyclosporin A. QJM. 1998; 91: 573-580.
8. Ogawa H, Kameda H, Nagasawa H, Sekiguchi N, Takei H, Tsuzaka K, Amano K, Takeuchi T. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod Rheumatol 2007; 17: 92-97.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25: 1271-1277.
10. Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984; 25: 689-695.
11. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982-992.
12. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sánchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology. 2010; 49: 128-140.
13. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med. 2008; 14: 931-938.
14. Machida H, Ito S, Hirose T, Takeshita F, Oshiro H, Nakamura T, Mori M, Inayama Y, Yan K, Kobayashi N, Yokota S. Expression of Toll-like receptor 9 in renal podocytes in childhood-onset active and inactive lupus nephritis. Nephron Dial Transplant. 2010; 25: 2530-2537.
15. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum. 2005; 52: 1676-1683.
16. Tsujimura S, Saito K, Nakayamada S, Nakano K, Tsukada J, Kohno K, Tanaka Y. Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells. 2004; 9: 1265-1273.
17. Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, Takahara J. Effect of low-dose cyclosporine A on systemic lupus erythematosus disease activity. Arthritis Rheum. 1994; 37: 551-558.
18. Baca V, Catalán T, Villasís-Keever M, Ramón G, Morales AM, Rodríguez-Leyva F. Effect of lowdose cyclosporine A in the treatment of refractory proteinuria in childhood-onset lupus nephritis. Lupus 2006; 15: 490-495.
19. Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, Nakanishi K, Yata N, Honda M. Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int. 2008; 73: 1167-1173.
20. Uchino A, Tsukamoto H, Nakashima H, Yoshizawa S, Furugo I, Mitoma H, Oryoji K, Shimoda T, Niiro H, Tada Y, Yano T, Nonaka T, Oishi R, Akashi K, Horiuchi T. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010; 28: 6-12.
21. Asamiya Y, Uchida K, Otsubo S, Takei T, Nitta K. Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center. Nephron Clin Pract. 2009; 113: c330-c336.